On Sep 3, 2019, at 8:53 AM, an SCC member emailed:

“The CMCR grant money was awarded —all for study of CBD . . . Is this cannabis? #sosickofCBD

Effects of Cannabidiol (CBD) versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action Kristin Cadenhead, MD (UC San Diego) $825,000

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis Veena Ranganath, MD (UCLA) $825,000

Cannabidiol for Sedative/Hypnotic-sparing Management of Insomnia in Adults Mariana Cherner, PhD (UC San Diego) $825,000

Cannabidiol as a Strategy to Treat Alcohol Dependence Giordano de Guglielmo, PhD (UC San Diego) $300,000

The Role of Cannabidiol (CBD) in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics Emily Gray, MD (UC San Diego) $300,000

Retro Message

Were researchers from Northern California allowed to apply?

The CMCR played a pivotal role in blocking the implementation of Prop 215 as envisioned by Dennis Peron and Tod Mikuriya. John Mikuriya pushed a funding bill through in ’98, I think, to create it; he specified that CMCR be located at UCSD as a personal favor to a close friend from high school! Tod Mikuriya wanted CMCR-funded studies conducted with California cannabis that patients were using in real time. Why go begging to the feds? Prop 215 had been a stunning rebuke to the federal  government. The CMCR kowtowed to federal law by insisting that researchers apply for NIDAwanna to use in their studies instead of contracting with California cultivators. Which they still won’t do. —Fred Gardner